Pyogenic granuloma

L12_PYOGENGRANUL

Hodgkins lymphoma: Hodgkin lymphoma (HL) is a heterogeneous group of malignant lymphoid neoplasms of B-cell origin characterized histologically by the presence of Hodgkin and Reed-Sternberg (HRS) cells in the vast majority of cases. There are two distinct subtypes: nodular lymphocyte predominant Hodgkin lymphoma and classical Hodgkin lymphoma. Hodgkin lymphoma involves primarily lymph nodes.

Endpoint definition

↥

FinnGen phenotype data

321302 individuals

Apply sex-specific rule None

321302

Check conditions None

321302

Filter registries

Hospital Discharge: ICD-10 L98.0

Hospital discharge: ICD-9 6861

Hospital discharge: ICD-8 68610

Cause of death: ICD-10 L98.0

Cause of death: ICD-9 6861

Cause of death: ICD-8 68610

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10, 8, 9 ; C.O.D: 10, 8, 9

Check minimum number of events None

Include endpoints None

318

L12_PYOGENGRANUL

Extra metadata

Level in the ICD hierarchy 4

First used in FinnGen datafreeze DF2

Parent code in ICD-10 L98

Name in latin Granuloma pyogenicum

Similar endpoints

↥

List of similar endpoints to Pyogenic granuloma based on the number of shared cases.

Broader endpoints:

Narrower endpoints:

None

Show all endpoint correlations

Summary Statistics

↥

Key figures

All

Female

Male

Number of individuals

308

175

133

Unadjusted prevalence (%)

0.10

Mean age at first event (years)

50.90

48.85

53.60

?

Follow-up

Amount of time to look for the endpoint since entering the study. This is either either 1, 5, 15 years or the full study time from 1998 to 2019.

Absolute risk

Estimates the probability of dying from the current endpoint. Check the Documentation page for Mortality: absolute risk to get more details.

Hazard Ratio (HR) and 95% Confidence Interval (CI)

Measures how much the risk of dying increases (HR > 1) or decreases (HR < 1).

Number of individuals (N)

Number of individuals having the current endpoint and died during the follow-up time.
Mortality

Follow-up	Absolute risk	HR [95% CI]	p	N
1998–2019	-	-	-	-
15 years	-	-	-	-
5 years	-	-	-	-
1 year	-	-	-	-

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

↥

Index endpoint: L12_PYOGENGRANUL – Pyogenic granuloma
GWS hits: 0

Survival analyses between endpoints

↥

Plot

before Pyogenic granuloma
after Pyogenic granuloma

Loading survival analyses plot

Table

Loading survival analyses table

Drugs most likely to be purchased after Pyogenic granuloma

↥